Magic: The Gathering is a popular trading card game that has been captivating players for decades. The game involves using spells, creatures, and strategies to defeat opponents and ultimately emerge victorious. One of the key elements that keeps the game interesting and fresh is the release of new sets of cards. These new sets often introduce never-before-seen cards and mechanics that add new layers of complexity to the game. To accompany the release of new sets, Wizards of the Coast, the company behind Magic: The Gathering, also produces booster packs. Booster packs are small packages that contain a random assortment of cards from the new set.
NEXOBRID is not recommended for wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance.
Epicel cultured epidermal autografts is authorized for use in adults and pediatric patients who have deep dermal or full thickness burns comprising a total body surface area greater than or equal to 30. Clinical studies of NEXOBRID did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects.
Booster packs are small packages that contain a random assortment of cards from the new set. These booster packs are a crucial element for players who want to expand their card collection and discover new cards to use in their decks. Magic: The Gathering booster packs are highly sought after by players and collectors alike.
Advanced Therapies
The U.S. Food and Drug Administration has approved MACI (autologous cultured chondrocytes on porcine collagen membrane) for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients. MACI is the first FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. Chronic knee pain affects millions of people across the U.S., but often goes untreated for long periods of time. Knee cartilage damage can occur from acute or repetitive trauma from playing sports, exercising, work-related physical demands, or performing everyday activities. A 2019 survey that Vericel conducted with The Harris Poll, found that 77% of chronic knee pain sufferers can no longer participate in at least one activity they enjoy because of their pain. While 74% of those with knee pain hope that their symptoms will resolve without treatment, knee cartilage does not heal on its own, and if left untreated, cartilage defects can progress. Learn More >
Indication and Important Safety Information
Indication
MACI ® (autologous cultured chondrocytes on porcine collagen membrane) is made up of your own (autologous) cells that are expanded and placed onto a film that is implanted into the area of the cartilage damage and absorbed back into your own tissue.
MACI is used for the repair of symptomatic cartilage damage of the adult knee.
The amount of MACI applied depends on the size of the cartilage damage. The MACI film is trimmed by your surgeon to match the size and shape of the damage, to ensure the damaged area is completely covered.
Limitations of Use
It is not known whether MACI is effective in joints other than the knee.
It is not known whether MACI is safe or effective in patients over the age of 55 years.
Important safety information
MACI should not be used if you:
- are allergic to antibiotics such as gentamicin, or materials that come from cow, pig, or ox;
- have severe osteoarthritis of the knee, other severe inflammatory conditions, infections or inflammation in the bone joint and other surrounding tissue, or blood clotting conditions;
- have had knee surgery in the past 6 months, not including surgery for obtaining a cartilage biopsy or a surgical procedure to prepare your knee for a MACI implant;
- or cannot follow a doctor-prescribed rehabilitation program after your surgery
Consult your doctor if you have cancer in the area of the cartilage biopsy or implant as the safety of MACI is not known in those cases.
Conditions that existed before your surgery, including meniscus tears, joint or ligament instability, or alignment problems should be evaluated and treated before or at the same time as the MACI implant.
MACI is not recommended if you are pregnant.
MACI has not been studied in patients younger than 18 or over 55 years of age.
Common side effects include joint pain, tendonitis, back pain, joint swelling, and joint effusion.
More serious side effects include joint pain, cartilage or meniscus injury, treatment failure, and osteoarthritis.
Please see Full Prescribing Information for more information.
Epicel is a cultured epidermal autograft (CEA)—a skin graft grown from a patient’s own skin. These grafts provide skin replacement for patients who have deep dermal or full thickness burns comprising a total body surface area (TBSA) of greater than or equal to 30%. From two postage stamp-sized biopsies, Vericel can grow enough skin to cover the patient’s entire body. Epicel is indicated for use in adult and pediatric patients who have deep dermal or full thickness burns comprising ≥ 30% total body surface area (TBSA). According to statistics kept by the American Burn Association, there are approximately 40,000 hospitalizations for burn injury per year, and of those approximately 10% (4000 patients) are admitted to hospitals with TBSA ≥30% (percentage derived from American Burn Association, Burn Injury Summary Report 2021). Therefore, the annual incidence reassessment (AIR) for the indicated use is assumed to be approximately 4000 patients. Learn more >
Indication and Important Safety Information
Humanitarian Device
Epicel (cultured epidermal autografts) is authorized for use in adults and pediatric patients who have deep dermal or full thickness burns comprising a total body surface area greater than or equal to 30%. It may be used in conjunction with split-thickness autografts, or alone in patients for whom split-thickness autografts may not be an option due to the severity and extent of their burns. The effectiveness of the device for this use has not been demonstrated.
Important Safety Information
Epicel is contraindicated in patients with a history of anaphylaxis following exposure to vancomycin, amikacin, and amphotericin, as trace quantities of these anti-infective agents may remain in the Epicel autograft. Epicel should not be used in patients with known sensitivities to materials of bovine or murine origin. It is contraindicated for use on clinically infected wounds.
Because Epicel is manufactured with and contains residual amounts of murine cells, FDA considers it a xenotransplantation product. Therefore, recipients should not donate whole blood, blood components, source plasma, source leukocytes, tissues, breast milk, ova, sperm, or other body parts for use in humans because there is a potential risk of carrying an infection that is transmitted from mouse cells to humans.
Squamous cell carcinoma (SCC) has been reported in patients with burn injury after being grafted with Epicel. Although SCC is a known complication of burn scars, the role of Epicel in the causation of SCC cannot be excluded.
The Epicel product is intended solely for autologous use. Patients undergoing the surgical procedure associated with Epicel are not routinely tested for transmissible infectious diseases. Discontinue use if the patient shows evidence of allergic reaction.
If clinical signs of infection are present or develop, do not apply Epicel until the infection is adequately treated.
The effectiveness of Epicel has not been proven in clinical studies.
The long-term safety of Epicel is unknown. Over the past 27 years, the mortality from all causes was 13% before hospital discharge.
Men and women who intend to have children should be advised tat the effects, if any, of Epicel on fetal development have not been assessed. In addition, the safety of Epicel has not been studied in pregnant and nursing women.
Patient information supplied by attending burn teams from 1989 to 1996 reported the adverse events of highest incidence as: death (13%), infection (13.8%), graft tear (7.8%) or graft blister (4.2%) and drainage (3.3%). Some of these events may have been due to the underlying burn injury and not the device itself.
From June 1998 through September, 2015 adverse events received by Genzyme Biosurgery (predecessor in interest to Vericel) and Vericel Corporation were similar to the previously identified adverse events. Events that were reported in ≥ 1% of patients included multi-organ failure (6.6%), sepsis (5.2%) infection (4%) and skin graft failure/graft complication (2.7%). The relationship of these events to Epicel has not been established.
Please see Patient Information and Directions for Use for more information
NexoBrid is a botanical drug product containing proteolytic enzymes indicated for the removal of eschar in adults with deep partial- and/or full-thickness thermal burns. A critical first step in the treatment of partial- and full-thickness burns is the rapid removal of nonviable burned tissue. Eschar removal involves removing layers of dead tissue from a burn wound. Following topical application of NexoBrid to burn eschar, a dressing is placed over the treatment area. After four hours, the eschar is removed and the wound bed is cleaned to make an assessment including burn depth, color implications and bleeding patterns. Learn more >
Indication and Important Safety Information
Indication
NexoBrid (anacaulase-bcdb) is indicated for eschar removal in adults with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.
Limitations of Use
The safety and effectiveness of NEXOBRID have not been established for treatment of:
- Chemical or electrical burns
- Burns on the face, perineum, or genitalia
- Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease
- Circumferential burns
- Burns in patients with significant cardiopulmonary disease, including inhalation injury
NEXOBRID is not recommended for wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance.
Important Safety Information
CONTRAINDICATIONS
NEXOBRID is contraindicated in patients with: known hypersensitivity to anacaulase-bcdb, bromelain, pineapples, or to any other components; known hypersensitivity to papayas or papain because of the risk of cross-sensitivity.
WARNINGS AND PRECAUTIONS
Hypersensitivity reactions
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarketing use of anacaulase-bcdb.
Pain Management
Manage pain as appropriate for an extensive dressing change of burn wounds. At least 15 minutes prior to NEXOBRID-related procedures ensure adequate pain control measures are in place.
Proteolytic Injury to Non-Target Tissues
NEXOBRID is not recommended for treatment of burn wounds where medical devices or vital structures could become exposed during eschar removal.
Coagulopathy
Avoid use of NEXOBRID in patients with uncontrolled disorders of coagulation. Use with caution in patients on anticoagulant therapy or other drugs affecting coagulation, and in patients with low platelet counts and increased risk of bleeding from other causes. Monitor patients for possible signs of coagulation abnormalities and signs of bleeding.
ADVERSE REACTIONS
The most common adverse reactions (>10%) were pruritus and pyrexia.
USE IN SPECIAL POPULATIONS
Geriatric Use
Clinical studies of NEXOBRID did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects.
To report negative side effects contact Vericel Corporation at 888-454-BURN (888-454-2876) or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.
The cards in these booster packs can range in rarity, with some cards being exceptionally rare and valuable. As a result, players and collectors often purchase many booster packs in hopes of obtaining these rare and valuable cards. Some collectors focus specifically on collecting these rare cards and view booster packs as a means to achieve their collecting goals. In recent years, Wizards of the Coast has introduced a new type of booster pack known as the collector booster. The collector booster is a premium version of the regular booster pack that contains a higher number of rare and valuable cards. These collector boosters are often sold at a higher price point, reflecting the increased value of the cards contained within. The collector booster packs are designed to cater to the needs and desires of collectors who are looking to amass rare and valuable cards. These packs often contain foiled versions of cards, as well as exclusive alternate art versions of popular cards. The inclusion of these special versions of cards makes the collector booster packs highly desirable among collectors. Overall, the introduction of the collector booster packs has added another layer of excitement and anticipation to the Magic: The Gathering community. These packs offer collectors a chance to obtain rare and valuable cards in a more efficient and targeted manner. Whether you are a player or a collector, opening a Magic: The Gathering collector booster pack can be an exhilarating experience, as you never know what rare and valuable cards you may find inside..
Reviews for "Discovering the Hidden Potential: Hidden Gems in Magic Collector Boosters"
1. Jack - 2 stars - I was really disappointed with the Magic collector booster. The cards inside were nothing special and definitely not worth the premium price. I was expecting to find some rare and powerful cards but instead, I got a bunch of average ones that I could have easily obtained in a regular booster pack. It felt like a waste of money, and I won't be buying another collector booster in the future.
2. Emily - 1 star - The Magic collector booster was a complete letdown for me. The packaging looked fancy, but the contents were extremely underwhelming. I expected to get some unique and exclusive cards, but all I got were duplicates of cards I already had. It was a total waste of money, and I felt ripped off. I would not recommend buying the collector booster unless you're okay with potentially getting cards you already own.
3. Alex - 2 stars - I had high expectations for the Magic collector booster, but it fell short in delivering anything special. The cards inside were not particularly rare or valuable, and the gameplay experience wasn't enhanced in any way. I was hoping for some unique artwork or alternate versions of popular cards, but unfortunately, it was just more of the same. Save your money and stick to regular booster packs if you're looking for a better variety of cards.
4. Jessica - 3 stars - While the Magic collector booster had a few interesting cards, it overall didn't meet my expectations. The chances of getting highly sought-after or valuable cards seemed quite low, and the premium price didn't feel justified. I think the booster could benefit from having more exclusive and rare cards to make it more appealing to collectors. It's not a terrible product, but it definitely didn't wow me either.
5. Ryan - 2 stars - I purchased the Magic collector booster hoping to find some unique additions to my collection, but I was left unimpressed. The cards inside were mostly duplicates of ones I already had, and there was nothing remarkable about them. For the price I paid, I was expecting more exclusive cards or at least some different artwork or foiling. Overall, I felt let down and wouldn't recommend the collector booster pack.